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Summary Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming
less ef®cient because of the increasing parasite resistance. Availability of HAT drugs is poor and their
production in danger because of technical, ecological and economic constraints. In view of this dramatic
situation, a network involving experts from NGOs, WHO and pharmaceutical producers was
commissioned with updating estimates of need for each HAT drug for the coming years; negotiations
with potential producers of new drugs such as e¯ornithine; securing sustainable manufacturing of
existing drugs; clinical research into new combinations of these drugs for ®rst and second-line
treatments; centralizing drug purchases and their distribution through a unique non-pro®t entity; and
addressing regulatory and legal issues concerning new drugs.
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Introduction
Human African Trypanosomiasis (HAT) or sleeping
sickness is a parasitic disease transmitted to man through
the bite of a tsetse ¯y. At the early or ®rst stage the features
of the disease ± recurrent fever, pain, weakness ± are not
speci®c apart from enlarged posterior cervical adenopathy.
Then, systemic manifestations occur, and at the second
stage the central nervous system becomes affected, leading
to intense suffering with severe psychiatric and neuro-
logical disturbances followed by cachexia, coma and
ultimately death. HAT is invariably fatal if untreated.
There are two forms of HAT, each caused by a different
parasite. Trypanosoma brucei gambiense causes a chronic
infectionlastingyearsandaffectingcountriesofwesternand
central Africa. Its reservoir is mainly human. T. b. rhodes-
iense causes acute illness lasting several weeks or months in
countries of eastern and southern Africa, fuelled by a large
animal reservoir. Thirty-six countries in West, East, Central
and southern Africa are affected; hence 55 million people
are ata risk ofcontracting thedisease, but only 4 million are
under surveillance. Thus the 25 000±40 000 cases reported
annually represent only part of the true caseload ± the real
incidence could be as many as 300 000±500 000 new cases
per year and the number of patients dying may be as high as
60 000 per year (WHO 1996).
By 1960, thanks to control programmes, most African
countries reported less than one to two new cases per
10 000 people every year. Over the last 15 years, the
disease has been ¯aring up again, because of a decline in
surveillance and control programmes and population
displacements, often linked to war. This is a spectacular
rebound; outbreaks frequently occur and 10±30% of the
population can be affected in some areas.
Treatments
Treatment differs according to the stages, related to the
capacity for the drug to go through the blood±brain
barrier. It may also differ according to the parasite.
Pentamidine isethionate is used for the treatment of early
stage HAT caused by T. b. gambiense infection. It is
administered daily or every other day by intramuscular
injection, 7±10 injections at a dose of 4 mg base per kg
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tension, abdominal pain, vertigo, hypersalivation and mild
nephrotoxicity, generally reversible. The drug is commer-
cially available at US$ 8±14 per vial from Sedapharm
(France) and Schein (USA). Due to a special agreement
with Rho Ãne-Poulenc Rorer (now Aventis), it is available
through WHO at US$ 3 per vial for treating HAT.
Suramin sodium (Germanin
Ò) is used for the treatment
of early stage HAT as a result of T. b. rhodesiense
infection. It is administered by a single weekly intramus-
cular injection for 6 weeks at a dose of 1 g per injection.
Most frequent adverse reactions are nausea, vomiting,
urticaria and less often renal damage and exfoliative
dermatitis. Suramin sodium is commercially available at
US$ 8 per vial from Bayer (Germany).
Melarsoprol (Arsobal
Ò) is used for treatment of the
second stage of the disease, when the central nervous
system is affected, in both T. b. gambiense and T. b.
rhodesiense infections. It is administered intravenously
usually in three series of three injections each, with a 7±10-
day rest period between series. The ®nal dose is 3.6 mg per
kg body weight. Several protocols have been developed in
an attempt to curb the severe adverse reactions: myocardial
damage, hypertension and exfoliative dermatitis. The most
serious side-effect is reactive encephalopathy, which occurs
in 5±10% of patients treated with melarsoprol; the case
fatality ratio is around 50%. The drug is commercially
available at US$ 8 per vial from Sedapharm (France).
E¯ornithine (Ornidyl
Ò) is used in the treatment of
second stage HAT caused by T. b. gambiense infection and
the only registered drug available for the treatment of
patients not responding to melarsoprol. It is administered
by intravenous infusion at a dose of 400 mg per kg body
weight evenly divided into four daily infusions (every 6 h)
for 7 or 14 days. Studies have shown that the 7-day
schedule is suitable in cases where melarsoprol has failed;
14 days is used in ®rst-line treatment. Adverse reactions are
mild and reversible: diarrhoea, seizure, anaemia, thrombo-
cytopenia, vomiting and fever. Marion Merrell Dow
stopped production when it merged with Hoechst and
Roussel.
Affordability and availability of these treatments
and reactions
In 1999, alarming news came from pharmaceutical com-
panies. The agreement concerning pentamidine isethionate
was revised by Aventis (Rho Ãne-Poulenc Rorer merged with
Hoechst Marion Roussel), proposing a progressive sub-
stantial cost increase. On several occasions, Bayer, which
maintained suramin production on the grounds that no
alternatives were available, threatened to stop it. They had
also planned to stop nifurtimox production. Problems in
Europe over manufacturing the raw materials required for
melarsoprol (containing arsenic, which is highly contro-
versial for ecological reasons) have rendered its production
uncertain.
In the ®eld, treatments rely on old drugs discovered
between 1922 and 1949 which are very toxic and dif®cult
to administer. A new drug was introduced in 1986 but its
production has been stopped. In fact, despite the re-emer-
gence of this disease, production of all HAT drugs is in
danger. Moreover, the standard treatment for second-stage
HAT, melarsoprol, is losing ef®cacy as a result of resistance
and relapses, especially in Angola, Southern Sudan, Congo
and northern Uganda where 25±30% of patients treated
with melarsoprol relapse (Legros et al. 1999).These recent
studies are worrying: they show that treatment failures are
directly because of the parasite, not the environment or the
patients. This means possible transmission and further
extension.
In view of disaster looming, non-toxic, available and
affordable drugs are urgently needed. But there is an
obvious lack of research and development: of 1223 new
molecules marketed between 1975 and 1997, only 11 were
for tropical diseases. Absence of pro®table markets is the
main reason; patients are numerous but they are so poor
that neither they nor their governments are able to pay,
even for essential drugs. This situation raised serious
concern and a number of yet unanswered questions. In
response, WHO created a network of ®eld researchers,
operational agents, epidemiologists and scientists from the
Swiss Tropical Institute, the Institute of Tropical Medicine
in Antwerp, the Centers for Disease Control (CDC),
Me Âdecins Sans Frontie Áres (MSF), Epicentre, WHO, Trop-
ical Diseases Research (TDR), industrial consultants and
others (WHO 1999). The stated mission of this network is
to `monitor drug resistance, ®nd and recommend solutions
for the treatment of sleeping sickness'. The objectives are to
assess the effectiveness of current regimens, to collect and
disseminate information on refractoriness to treatment, to
ensure availability and affordability of existing drugs, to
provide guidelines and promote research on the causes of
treatment failures, drugs and treatments. The network
consists of a steering committee, a secretariat and four
technical working groups responsible for research, sur-
veillance, drugs and information.
The objectives of the drug group, led jointly by MSF and
WHO, are to secure and maintain production of anti-
trypanosomiasis drugs. It is planned to centralize drug
purchases, group the orders and dispatch them to
requesting programmes through the MSF purchasing
centre. A special fund to secure the market and to sustain
drug production will be necessary. Another immediate
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and registration of e¯ornithine in Africa and Europe.
Since April 1999 the situation has slightly improved:
Production of melarsoprol, suramin and nifurtimox seems
to be secure, the donation of pentamidine vials was
extended through 2000, and discussions for a new agree-
ment should take place soon. WHO and MSF are trying to
®nd alternative producers for e¯ornithine. The high cost of
this drug is a major concern and technical procedures need
to be set up to make this drug affordable.
Research and development
Burri et al. (2000) recently established the viability of a
shorter, 10-day regimen for melarsoprol treatment. Nifur-
timox (Lampit
R), a registered drug used for treating
American trypanosomiasis or Chagas' disease, requires
more research into its pharmacokinetics and bioavailability
to de®ne the treatment protocol for the second stage of
HAT before it can be registered for prescription in endemic
countries. Berenil is highly ef®cient in animals and should
be tested for human trypanosomiasis. Some producers have
shown interest, and it may be be possible to get support
from the European Orphan Drug Act. Megazol, a nitro-
imidazole drug, has only been tried on monkeys and
produced very good results. It is under further investigation
and will not be available for some years yet. Various drug
combinations are also being considered and some of them
are under investigation.
Conclusions
We hope that the network initiated by WHO will succeed
in sustaining the manufacturing of HAT drugs and
encourage the research and development of new ones. This
is an emergency ± we may not be able to treat patients soon
due to the scarcity of existing drugs and the lack of new
ones against this fatal disease.
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